Dbv Technologies SA at JMP Securities Life Sciences Conference Transcript
Welcome everyone to day-one of the JMP Life Sciences Conference. My name is John Walden, senior analyst here. We're pleased to kick off the day and the conference this morning with DBV Technologies and CEO, Daniel Tassé.
©,-
Good morning, all.
Thank you for coming. And I think you people have been following the story for a little bit of time. They know you're working on peanut allergy. But we have a lot of new news coming in the past couple of weeks. Some developments I want to get into. But maybe can you give a little bit of a history of the company? Because it's been some twists and turns. And then maybe that gets at the stage, we're talking about the technology and then we can get into the news in the past couple of weeks.
©,-
I'll be happy to do so. So we're an immunology
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |